ArticleCommunications biology2025
HBV DNA integration gene CCDC91 is oncogenic and a potential therapeutic target for hepatocellular carcinoma.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic structural equation modelling of 12 cancers identifies a latent pan-cancer susceptibility factor and shared determinants of carcinogenesis.EBioMedicine · 2026Article
- Landscape and biogenesis of piRNAs in HBV-associated hepatocarcinogenesis: from repetitive elements to oncogenic circuits.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) integration is strongly associated with hepatocellular carcinoma (HCC). However, the genetic alterations and pathogenesis mechanisms remain significantly unexplored, especially for HBV-inserted cancer-related genes. This study identified recurrent HBV DNA integration into the CCDC91 gene in HCC tissues (n = 17) using pooled analysis and HBV capture sequencing. CCDC91 expression was positively correlated with HBV DNA presence, and higher levels were linked to shorter overall survival in HCC patients. CCDC91 was upregulated in HCC and promoted HCC malignancy in vitro and in vivo. CCDC91 deficiency increased sensitivity to sorafenib treatment. By RNA sequencing and co-immunoprecipitation assays, we further demonstrated that the Ct-HBx upregulated CCDC91 and that CCDC91 induced aerobic glycolysis by activating LDHA to drive HCC progression. In conclusion, the HBV integrated gene CCDC91 is a novel HCC-related gene that functions through the Ct-HBx/CCDC91/LDHA axis. Our work sheds light on the mechanism in driving HCC progression and sorafenib resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.